Prevalence of clinically actionable genotypes and medication exposure of older adults in the community
Open Access
- 1 January 2017
- journal article
- research article
- Published by Taylor & Francis in Pharmacogenomics and Personalized Medicine
- Vol. ume10, 17-27
Abstract
This study analyzed clinically actionable pharmacogenotypes for clopidogrel, warfarin, statins, thiopurines, and tacrolimus using microarray data for 2121 participants (55–85 years) from the Australian Hunter Community Study (HCS). At least 74% of participants (95% confidence interval [CI]: 72%–76%) had strong level evidence for at least one medium- or high-risk actionable genotype that would trigger a change in standard therapy under current international recommendations. About 14% of these participants (95% CI: 12%–16%) were taking medication potentially affected by the genotype in question. Furthermore, ~2.6% of all participants with medication data (95% CI: 1.4%–3.8%) had a high-risk clinically actionable genotype for a medication to which they were exposed. This represents a considerable number of people at the population level. Although relationships between genotype and health outcomes remain contentious, pharmacogenotyping of multiple variants simultaneously may have considerable potential to improve medication safety and efficacy for older people in the community.Keywords
This publication has 40 references indexed in Scilit:
- An expanded pharmacogenomics warfarin dosing table with utility in generalised dosing guidanceThrombosis and Haemostasis, 2016
- Precision Medicine: The new era in medicineEBioMedicine, 2016
- Pharmacogenomics in the clinicNature, 2015
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus DosingClinical Pharmacology & Therapeutics, 2015
- How Common are Drug and Gene Interactions? Prevalence in a Sample of 1143 Patients with CYP2C9 , CYP2C19 and CYP2D6 GenotypingPharmacogenomics, 2014
- Clinically Actionable Genotypes Among BraziliansClinical Pharmacology & Therapeutics, 2014
- Clinically Actionable Genotypes Among 10,000 Patients With Preemptive Pharmacogenomic TestingClinical Pharmacology & Therapeutics, 2013
- The potential impact of pharmacogenetic testing on medication adherenceThe Pharmacogenomics Journal, 2013
- Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 UpdateClinical Pharmacology & Therapeutics, 2013
- Warfarin therapy in a patient homozygous for the CYP2C9 3 allele.2002